The MyoKardia Crew Is Back, and Wall Street Just Handed Them $400 Million
The team that built MyoKardia into a $13 billion acquisition just pulled off one of 2026's biggest biotech IPOs. Kardigan raised $400 million at the top of its range, and the story behind the deal says as much about the market as it does about the company.
In 2020, Bristol Myers Squibb paid $13 billion to buy MyoKardia, a cardiovascular biotech that most people outside of healthcare had never heard of. The founders cashed out. The science lived on. And for a few years, the team behind that blockbuster exit went quiet.
Now they're back. And investors are throwing money at them like it's a reunion tour for their favorite band.
The Biggest Biotech Debut Nobody Saw Coming
Kardigan, a cardiovascular biotech founded in 2023 by former MyoKardia executives, just priced a $400 million IPO on Nasdaq. Shares went for $16 apiece, the top of the marketed range. The offering was upsized from the original plan of 23.3 million shares to 25 million shares. And if underwriters exercise their full option, gross proceeds could stretch to roughly $460 million.
For context, that makes Kardigan one of the larger biotech IPOs of 2026, in a year that's already seen some monsters. Parabilis Medicines raised $670 million at pricing in its IPO earlier this year; Kailera pulled in approximately $625 million at pricing. Kardigan's debut slots comfortably into the upper tier.
The company trades under the ticker KARD, with J.P. Morgan, Jefferies, Leerink Partners, and TD Cowen running the books.
The Team That Built a $13 Billion Exit
Kardigan's founding story reads like a heist sequel: the same crew, a new target, bigger ambitions.
CEO Tassos Gianakakos co-founded Kardigan and ran MyoKardia as CEO until the BMS acquisition. Chief Medical Officer Jay Edelberg and Chief Scientific Officer Bob McDowell are fellow Kardigan co-founders who held key roles at MyoKardia. Together, this group discovered the first class of cardiac myosin inhibitors, a type of drug that directly tweaks how heart muscle proteins work.
After selling MyoKardia, they regrouped and launched Kardigan with a straightforward thesis: there are serious cardiovascular diseases with , and they know how to build drugs for the heart better than almost anyone.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
zero approved treatments
That pedigree attracted serious money before the IPO ever happened. Kardigan raised $300 million in a Series A led by Perceptive Advisors, ARCH Venture Partners, and Sequoia Heritage. A $254 million Series B followed, bringing in Fidelity and T. Rowe Price. Total pre-IPO funding: north of $550 million.
So the $400 million IPO isn't a starting gun. It's jet fuel for a rocket that was already moving.
Three Drugs, One Big Bet on the Heart
Kardigan's pipeline is tightly focused on cardiovascular disease, which is a refreshing change from the "platform for everything" approach that burned so many investors during the 2020 boom.
The lead program is danicamtiv, a direct myosin activator (think of it as a molecule that helps weakened heart muscle contract more forcefully). It's being tested in a Phase 2b/3 trial called KINSHIP-DCM for genetic dilated cardiomyopathy, a hereditary condition where the heart's main pumping chamber stretches out and weakens. There's currently no approved drug for it.
Behind that sit two more programs, both in Phase 2b trials:
Ataciguat targets moderate calcific aortic valve stenosis, a condition where calcium deposits stiffen a critical heart valve. Again, no approved therapy exists.
Tonlamarsen goes after acute severe hypertension, the kind of blood pressure spike that sends people to the emergency room.
All three indications share a common thread: patients are underserved, and the market opportunity is real. That combination of unmet need and late-stage data is exactly what 2026 investors want to see.
Why This IPO Says More About the Market Than About Kardigan
Pricing at the top of the range and upsizing the deal is the biotech IPO equivalent of a restaurant with a two-hour wait. Demand clearly outstripped supply. But zoom out, and Kardigan's debut tells a bigger story about where biotech capital is flowing right now.
The IPO window has been creaking back open after a brutal stretch. In 2025, only about 10 U.S. biotech firms went public, raising a combined $1.6 billion. Compare that to 2021, when more than 100 companies listed. The market was effectively shut for all but the most compelling stories.
2026 has been a different animal. In Q1 alone, biopharma companies raised $1.7 billion through IPOs, matching all of 2025 in a single quarter. The median IPO size more than doubled from the prior year. But this isn't a return to the spray-and-pray era. It's a selective reopening.
Investors are backing late-stage companies with real clinical data, experienced teams, and capital discipline. Think of it like a bouncer at an exclusive club: the door is open, but you need to be on the list. Kardigan, with its proven founders and three clinical-stage programs, had VIP access.
The Fine Print Worth Noticing
One detail that tempers the celebration: Kardigan reportedly priced at a 25% discount to its Series B share price. That means public investors got a better deal than the private backers who wrote checks just months earlier.
This isn't unusual in the current market. Even when demand is strong, public investors are pushing for disciplined entry points. They want upside, and they're not willing to pay the same premium that late-stage venture funds accepted. It's a sign of a market that's recovering but hasn't lost its skepticism; cautious optimism rather than blind enthusiasm.
The discount also reflects a broader dynamic in 2026: M&A is still the dominant force in biotech exits, not IPOs. Big pharma companies are sitting on massive balance sheets and facing a looming patent cliff, which means they need to buy pipelines. Many investors are now underwriting IPO shares with one eye on a potential acquisition within 12 to 24 months. In other words, some people buying KARD stock might be betting that a larger pharma eventually buys the whole company.
Given that the same team already engineered a $13 billion takeout, that's not a crazy bet.
What Happens Next
Kardigan now has a war chest of roughly $660–$690 million when you combine its cash on hand with the IPO proceeds. That's serious firepower for a company running three clinical programs, and it should provide plenty of runway to generate the Phase 3 data that will ultimately determine its fate.
The KINSHIP-DCM trial for danicamtiv is the one to watch. If the data holds up, Kardigan could be sitting on the first approved treatment for genetic dilated cardiomyopathy. If it doesn't, that $400 million IPO will look a lot less impressive in hindsight.
For now, though, Kardigan's debut is proof that the biotech IPO market rewards a specific recipe in 2026: late-stage programs, unmet medical need, capital efficiency, and a team that's done it before. Miss any of those ingredients, and you're probably still stuck in the private markets, hoping the M&A phone rings.
Kardigan checked every box. The market noticed.
5 min read
Lilly's $25 Billion Shopping Spree Just Found a Painkiller That Skips the Opioid Problem
Eli Lilly quietly scooped up 4E Therapeutics, a startup with a first-in-class painkiller that skips opioid receptors entirely. It's the latest move in a $20 billion+ acquisition spree, and it could reshape how we treat chronic pain.
